

Sponsors

Alphabetical list of companies with stand numbers and product descriptions

Abbott Laboratories

4-7

200 Abbott Park Road
Abbott Park, IL 60064
United States of America

Contact: Ms. Lori Pearl
Tel: + 1 847 938 6918 - Fax: + 1 847 937 6076
Email: lori.pearl@abbott.com

SIMDAX® is an intravenously administered agent for the treatment of acutely decompensated heart failure. It is the first in a novel class of calcium sensitizer drugs.

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.

Acorn Cardiovascular Inc

5-5

601 Campus Drive
St Paul MN 55112
United States of America

Contact: Ms. Patti Hatchett
Tel: +1 651 286 4800 - Fax: +1 651 286 4848
Email: patti-hatchett@acorncv.com

Arrow International

1-6

Lambroekstraat 5c
1831 Diegem
Belgium

Contact: Ms An Cherlet
Tel: + 32 2 7190316 - Fax: + 32 2 7190317
email: an.cherlet@arrowint-europe.com

The worldwide technology leader in Cardiac Assist has new technology for Intra-Aortic Balloon pumps and catheters, and LVAD's. Come see our new FiberOptix sensor in the new AutoCAT™ 2 WAVE™ pump console and LightWAVE™ catheter. The AutoCAT 2 WAVE also offers a unique timing software called WAVE and the revolutionary AutoPilot 2 mode of operation, our 2nd generation of simplicity. The LionHeart™ LVAD is now CE marked and is the only fully implantable LVAD designed for destination therapy of heart failure patients. The LionHeart features pulsatile flow with transcutaneous energy transmission offering patient's hope and a good quality of life.

Sponsors

AstraZeneca

2-1

SE-43183 Mölndal
Sweden

Contact: Mrs. Marianne Weimers
Tel: + 46 31 776 1000 - Fax: + 46 31 776 3784
email: marianne.weimers@astrazeneca.com

AstraZeneca is one of the world's leading pharmaceutical companies.

AstraZeneca has a comprehensive portfolio of cardiovascular products aimed to reduce the risk, prevalence and impact of cardiovascular disease.

Cardiovascular products include Atacand, the AT1 - receptor blocker (ARB) for use in hypertension and heart failure, as well as Atacand Plus/Hytacand, its combination with a diuretic for the treatment of hypertension and Seloken ZOK/Toprol-XL (not available in Portugal), the world's leading cardioselective beta-blocker.

This heritage is complemented by CRESTOR, a new highly effective statin (HMG-CoA reductase inhibitor) which is supported by an extensive clinical trials programme; the GALAXY Programme. The most recent products in development include ximelagatran, the first oral treatment in a new class of direct thrombin inhibitors (DTIs) being developed for the prevention and treatment of thromboembolic disorders. Exanta (ximelagatran) is approved in EU for the prevention of venous thromboembolic events in elective hip or knee replacement surgery. Tesaglitazar, another product in development, is a novel dual PPAR α/γ agonist for treating the glucose and lipid abnormalities associated with type 2 diabetes and the metabolic syndrome. With corporate headquarters situated in the UK, AstraZeneca has research and manufacturing sites all over the world. The R&D headquarters for Cardiovascular Medicine is situated in Mölndal, Sweden.

Berlin Heart AG

5-2

Wiesenweg 10
12247 Berlin
Germany

Contact: Ms. Katrin Neiss
Tel: + 49 30 818 72650 - Fax: + 49 30 818 7222650
email: neiss@berlinheart.de

INCOR® - implantable third generation axial flow LVAD system with unique contact free magnetically levitated impeller.

EXCOR® - extracorporeal pneumatically driven Uni/BiVAD system with a full range of pumps and cannulas for support of all patient sizes from newborn to adult.

Biosite Europe

3-2

1232 Rue Louis Blériot
78530 Buc
France

Contact: Mr. Didier Dubreuil
Tel: + 33 1 39 20 21 10 - Fax: + 33 1 39 20 21 01
email: intlenquiry@biosite.com

Sponsors

Blackwell Futura Ltd

1-1

9600 Garsington Road
Oxford OX4 2DQ
United Kingdom

Contact: Ms. Anne Weston
Tel: +44 1865 476 380 - Fax: +44 1865 471 380
email: anne.weston@oxon.blackwellpublishing.com

CardioDynamics

1-5

6175 Nancy Ridge Dr
92121 San Diego, CA
United States of America

Contact: Mr. Rich Trayler
Tel: + 1 858 535 0202 - ext 1042 - Fax: + 1 801 659 5977
email: rtrayler@cdic.com

PREDICT Trial identified the BioZ ICG Score as the most powerful predictor of future heart failure events. Come to the CardioDynamics Booth to learn more about the results of this multi-center trial and see the BioZ, Dx, ICG Module for GE Patient Monitors, Medis Niccomo, and CardioScreen ICG Monitoring Systems.

Elsevier

5-6

Radarweg 29
1043 NX
The Hague
Netherlands

Contact: Ms. Roshnie Kandhai
Tel: + 31 20 485 3799 - Tel: + 31 20 485 3809
email: R.Kandhai@elsevier.com

European Society of Cardiology

4-2

The European Heart House
2035 Route des Colles
Les Templiers - B.P. 179
FR-06903 Sophia Antipolis Cédex
France

Contact: Ms. Svyta Karaim Fanchon
Tel: + 33 4 92 94 86 87 - Fax: + 33 4 92 94 86 69
email: skaraimfanchon@escardio.org

The European Society of Cardiology (ESC) represents more than 45,000 cardiology professionals across Europe and the Mediterranean basin. Its mission is to improve the quality of life of the European population by reducing the impact of cardiovascular disease. The next ESC Congress will be held from 3-7 September 2005 in Stockholm, Sweden.

Sponsors

GE Healthcare

1-3

POB 4220 Nydalen
0401 Oslo
Norway

Contact: Ms. Nina Taaje
Tel: + 472 318 51 15 - Fax: + 472 318 60 10
email: nina.taaje@ge.com

GE Healthcare provides medical technologies and healthcare products that are shaping a new age of patient care. Our expertise in medical imaging is dedicated to detecting disease earlier, improving diagnostic information, and enabling Personalized Healthcare. Worldwide, GE Healthcare employs more than 42,500 people committed to serving healthcare professionals and their patients in more than 100 countries.

Guidant Europe

4-4

Park Lane
Culliganlaan 2B
1831 Diegem
Belgium

Contact: Ms Jacky Melikian
Tel: + 32 2 714 1479 - Fax: + 32 2 714 1455
email: jmelikian@guidant.com

GUIDANT is a world leader in the treatment of cardiovascular diseases. The company offers a wide range of innovative products in several therapy areas, Cardiac Rhythm Management, Heart Failure Management, Vascular Intervention, Endo-vascular Solutions and Cardiac Surgery. Cardiac Resynchronization Therapy for heart failure, pioneered by GUIDANT, offers significant improvement in quality of life, reduced hospitalization and mortality in heart failure patients as recently demonstrated in the COMPANION trial.

GUIDANT is strongly committed to education for clinicians. Programs at the Institute for Therapy Advancement Europe are designed and moderated by experts with extensive practical clinical experience and proven teaching competency.

Innovision A/S

1-2

Lindvedvej 75
DK-5260 Odense S
Denmark

Contact: Ms. Charlotte Skrydstrup Henningsen
Tel: +45 63 10 06 09 - Fax: +45 65 95 78 00
email: cs@innovision.dk

Innocor®. The device for applications in cardiology and hypertension using inert gas rebreathing, providing the technology to perform a non-invasive measurement of CO at rest and in exercise. Recently an ergospirometry option was added providing the possibility to do a combined exercise test with the full set of metabolic/hemodynamic data.

Sponsors

Medtronic Europe Sarl

3-5

Route du Moliau 31
CH-1131 Tolochenaz
Switzerland

Contact: Ms. Claire Marie Gigon
Tel: + 41 21 802 7036 - Fax: + 41 21 802 7900
email: claire.marie.gigon@medtronic.com

World leader in medical technology, Medtronic brings device therapy to Heart Failure.

Visit our booth for information on:

- The latest HF device trials, including Medtronic sponsored CARE-HF, SCD-HeFT, and COMPASS-HF
- Revolutionary diagnostics for managing HF patients, including fluid status monitoring with OptiVol™ Guided Therapy
- Newest information on Cardiac Resynchronization Therapy (CRT)

Menarini International

3-7

Via Sette Santi 1
50131 Florence
Italy

Contact: Mr Antonio Gucci
Tel: + 39 0555 680414 - Fax: + 39 0555 980484
email: agucci@menarini.it

Menarini is the largest Italian pharmaceutical group. Menarini is in the world top 40 Pharmaceutical Companies and one of the biggest players in Europe. Menarini is also present in more than 100 countries world-wide with its products. Menarini is mainly involved in cardiovascular field, oncology, pain-inflammation and asthma. Nebivolol is a newly introduced anti-hypertensive drug, which uniquely combines Nitric Oxide mediated vasodilation with highly cardio-selective beta-adrenergic blocking action. Zofenopril is an efficacious anti-hypertensive treatment that has demonstrated a reduction of long-term cardiovascular events. Olmesartan is the newest potent ARB, effective in the treatment of all grades of hypertension.

Sponsors

Merck KGaA

2-11

Frankfurter Str. 250
64293 Darmstadt
Germany

Contact: Mr. Karl-Benno Bauer
Tel: + 49 6151 727 382 - Fax: + 49 6151 7291 7382
email: karl-benno.bauer@merck.de

Bisoprolol in CHF

Bisoprolol successfully demonstrated in CIBIS II (Cardiac Bisoprolol Insufficiency Study) that this β 1-selective β -blocker - concomitantly administered to standard therapy – reduces all-cause mortality significantly by 34%.

The ongoing CIBIS III study will reveal whether there is any advantage in starting CHF treatment with a β -blocker before an ACE inhibitor in terms of all-cause mortality and all-cause hospitalization. Bisoprolol for CHF treatment is known as e.g. Bicolor®, Concor® COR, Cardicor®, Cardensiel®, Concor® IC, Congescor®, Emconcor® CHF, Emconcor® COR, Emconcor® minor and Emcor® DECO.

Myogen GmbH

1-10

Rochusstrasse 175-177
53113 Bonn
Germany

Contact: Mr. Ernst H. Schneider
Tel: +49 228 74879 0 - Fax: +49 228 74879 20
email: ernst.schneider@myogen.de

Myogen Inc. (NASDAQ:MYOG) is a biopharmaceutical, public company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders. Myogen GmbH is the European headquarter of Myogen Inc.. We market Perfan I.V. (acute decompensated heart failure), and we have three product candidates in clinical development: enoximone capsules (chronic heart failure), ambrisentan (pulmonary arterial hypertension) and darusentan (uncontrolled hypertension).

www.perfan.com or www.myogen.com

Sponsors

Novartis Pharma AG

2-13

Lichstrasse 35
WSJ-310.122
CH-4002 Basel
Switzerland

Contact: Mr. Fritz Baldus
Tel: + 41 61 324 3655 - Fax: + 41 61 324 9944
email: fritz.baldus@pharma.novartis.com

Novartis AG (NYSE: NVS) is a world leader in pharmaceuticals and consumer health. In 2003, the Group's businesses achieved sales of USD 24.9 billion and a net income of USD 5.0 billion. The Group invested approximately USD 3.8 billion in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ about 78 500 people and operate in over 140 countries around the world. For further information please consult www.novartis.com.

Orqis International GmbH

5-3

14 Orchard Road, Suite 100
92630 Lake Forest, CA
United States of America

Contact: Mr. Todd Canfield
Tel: + 1 949 268 0172 - Fax: + 1 949 707 5894
email: todd@orqis.com

Pfizer Inc.

4-1

235 East, 42nd Street
NY10017, New York
United States of America

Contact: Mrs. Kirsten Flowers
Tel: + 1 212 733 2323 - Fax: + 1 212 309 0884
email: kirsten.flowers@pfizer.com

Introducing INSPRA. Less Risk. More Survival™. Pfizer, a world leader in cardiovascular research, is dedicated to help improve the management of heart failure. Inspra (eplerenone), the newly launched innovative product from Pfizer, dramatically reduces morbidity and mortality in patients with acute myocardial infarction (MI) complicated by symptoms of heart failure.

Respironics International

1-7

77, rue de Paris
92100 Boulogne-Billancourt
France

Contact: Ms. Manuela Leurent
Tel: +33 1 55 60 19 86 - Fax: +33 1 55 60 19 89
email: manuela.leurent@respironics.com

Sponsors

Roche Diagnostics GmbH

1-0

Sandhofer Str. 16
DE-68305 Mannheim
Germany

Contact: Ms. Kerstin Jaeger
Tel: + 49 621 759 6450 - Fax: + 49 621 759 2323
email: dirk-volker.stucken@roche.com

Sigma Tau Industrie Farmaceutiche Riunite SPA

4-5

Via Pontina KM 30,400
00040 Pomezia - Rome
Italy
Tel. + 39 06 913268 - Fax. +39 06 91393979
email: silvia.sciotti@sigma-tau.it

Sigma-tau is one of the most important pharmaceutical companies in Italy, with a leading position in the field of scientific research.

Every year 16% of the company's total turnover (620 million Euro in 2003) is invested in research and development.

Out of a total of 2,416 company employees, 18% are working on research projects.

Sigma-tau's projects include important medical and biological research programs in collaboration with some of the most prestigious scientific institutions in the US and Europe.

The main R&D activities are concentrated in the following research centres:

- The Sigma-tau Research Centre in Pomezia, Rome, Italy for the development of active substances for the cardiovascular system, metabolism, oncology, immunology, diabetes, gastroenterology, brain aging and neurodegenerative disorders.
- The Prassis Research Institute in Milan, Italy for research into factors causing hypertension and other cardiovascular disorders.
- Tecnogen, a biotechnology research company based in Caserta, Italy specialising in the study and development of new radio-immunological substances.
- Kenton, Italy, a biotechnology research company specialising in diagnostic applications for oncology and hepatitis C.
- Sigma-tau Research Inc. USA focusing on research and development programs for the US market.

These research activities currently employ more than 400 researchers.

Sponsors

St Jude Medical

2-17

The Corporate Village
Avenue da Vinci Laan 11 - Box F-1
B-1935 Zaventem
Belgium

Contact: Ms. Tassula Tillberg
Tel: + 32 2774 68 11 - Fax: + 32 2774 68 43
email: ttillberg@sjm.com

St. Jude Medical is a global leader in cardiovascular devices, offering new perspectives in cardiac care. St. Jude Medical has innovative and effective new approaches for the treatment of the two major healthcare challenges: Atrial Fibrillation (AF) and Heart Failure (HF).

Synovate Healthcare

4-3

The Boathouse
The Embankment
Putney
London SW15 1LB
United Kingdom

Contact: Rebecca Walker
Tel: + 44 208 246 6237 - Fax: + 44 208 246 6300
email: healthcare@synovate.com

Synovate Healthcare is an independent market research agency specialising 100% in pharmaceuticals and healthcare. Our specialist conference research team is present at Heart Failure 2005 to conduct research among delegates. We look forward to speaking to you, and listening to your opinions and experience.

Takeda Pharmaceutical Company Ltd

4-13

14 Waterloo Place
London SW17 4AR
United Kingdom

Contact: Mr. Marcus Taylor
Tel: + 44 207 849 082 - Fax: + 44 2 074 849 079
email: m.taylor@takeda-eurd.co.uk

Takeda Pharmaceutical Company Limited is a research-based. It is the largest pharmaceutical company in Japan and is among the world leaders.

They are committed to developing a range of innovative new products in a wide range of therapeutic areas, including candesartan cilexetil (Blopress®, Kenzen® and Amias®) and pioglitazone (Actos®).

Sponsors

Terumo Heart Inc

1-4

Siemensstrasse 1
46325 Borken
Germany

Contact: Ms. Ingrid Craninckx
Tel: + 49 2 861 808 208 - Fax: + 49 2 861 605 010
email: ingrid.craninckx@terumo-europe.com

Terumo Heart, Inc. is a global leader in the development and design of Ventricular Assist Devices (VADs). With the DuraHeart™ LVAS the company has successfully entered this market with the only actively magnetically levitated, third generation system centrifugal LVAD. This unique design allows for no contact points within the blood chamber, thereby further minimizing the risk of mechanical wear and thrombus formation. The DuraHeart™ LVAS is currently in clinical trials in Europe, and is expected to initiate commercial sales in Europe in the near future.

Thoratec Corporation

1-13

6035 Stonebridge Drive,
Pleasanton
CA 94588
United States of America

Contact: Sandie Hastings
Tel: + 1 925 847 8600 - Fax: + 1 925 847 8574
email: sandie.hastings@thoratec.com

Thoratec® Corporation, a world leader in circulatory support, provides a broad range of complementary cardiac assist products for the treatment of congestive heart failure. As a single, trusted source, only Thoratec offers both implantable and paracorporeal ventricular assist devices. Our HeartMate® LVAS and Thoratec VAD Systems are ideally suited for short to long-term, left, right or biventricular support in patients of almost any size.

Vifor (International) Inc.

1-12

Rechenstrasse 37 (P.O. Box)
CH - 9001 St. Gallen
Switzerland

Contact: Mr. Mehran Nouroozian
Tel: + 41 71 272 8484 - Fax: + 41 71 272 8485
Email: mnouroozian@viforint.ch

Vifor (International) is a Swiss based company specialized in research, development and marketing of pharmaceutical iron preparation worldwide for the treatment of iron deficiency anemia. Venofer®, the intravenous iron preparation (iron sucrose), since 2000 FDA approved, has become rapidly the number one prescribed intravenous iron preparation worldwide. The absence of dextran gives Venofer® an unprecedented safety profile as a hematinic of choice for a variety of disorders, ranging from the iron deficiency anemia of CKD to anemia associated with surgery and post surgical period.

Sponsors

Wisepress Online Bookshop Ltd

5-4

The Old Lamp Works
25 High Path
Merton Abbey
London SW19 2JL
United Kingdom

Contact: Ms. Abigail Spearing
Tel: + 44 208 715 1812 - Fax: + 44 208 715 1722
email: bookshop@wisepress.co.uk

The Heart Failure Association of the
European Society of Cardiology
gratefully acknowledges the support of
its partners during its Annual Meeting